Novartis buys access to Spark’s vision loss therapy
admin 25th January 2018 Uncategorised 0Novartis has bought itself rights to Spark Therapeutic’s gene therapy for a certain type of vision loss, in a deal worth up to $170 million.
More: Novartis buys access to Spark’s vision loss therapy
Source: News